24/7 Market News Snapshot 19 February, 2025 – ImmunityBio, Inc. Common Stock (NASDAQ:IBRX)

February 19, 2025

DENVER, Colo., 19 February, 2025 (247marketnews.com) – (NASDAQ:IBRX) are discussed in this article.
ImmunityBio, Inc. (NASDAQ:IBRX) is experiencing significant market momentum, with shares jumping from a previous closing price of $3.35 to a current trading level of $3.995, reflecting a robust increase of 19.25%. This surge is accompanied by heightened investor interest, as evidenced by a trading volume of 7.37 million shares today. Despite the positive trend, analysts suggest that technical indicators might indicate resistance levels around $4.00, while support could stabilize closer to the stock’s prior closing price. Investors are cautioned to remain vigilant of potential fluctuations as the stock approaches these critical levels.

In parallel, ImmunityBio has announced the authorization of an expanded access program (EAP) by the U.S. Food and Drug Administration (FDA) to provide a vital alternative source of Bacillus Calmette-Guerin (BCG) for bladder cancer patients. This initiative is timely, given the ongoing shortage of TICE® BCG, which has left many patients without adequate treatment options. A recent survey of 100 urologists revealed that 57% faced challenges in adequately treating their patients over the past year due to BCG accessibility issues.

The alternative BCG developed in collaboration with the Serum Institute of India demonstrates enhanced immunogenicity and safety, having shown encouraging results in clinical trials conducted in Europe. This development is particularly significant for patients with non-muscle invasive bladder cancer (NMIBC). Dr. Patrick Soon-Shiong, Founder and Executive Chairman of ImmunityBio, highlighted the company’s dedication to innovating solutions that confront critical healthcare shortages.

As ImmunityBio continues to advance in the field of immunotherapy, this EAP underscores its commitment to improving patient access to vital treatments and enhancing therapeutic alternatives in bladder cancer management.

Related news for (IBRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.